Paper Details

  1. Home
  2. Paper Details

Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.

Author: DavisJohn C, HiebertLori, IonescuMirela, KingLindsay, LobanokTatiana, MaksymowychWalter P, PooleA Robin, WebbAlison

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

While medications that block TNF-alpha have been shown to improve symptoms and reduce joint damage in rheumatoid arthritis (RA), it is unknown if they have the same protective effect on joint damage in ankylosing spondylitis (AS). This study aims to investigate whether these medications impact biomarkers of cartilage damage in AS, as traditional X-ray imaging is not sensitive enough to detect subtle changes over time.
Paper Details　
Original Abstract of the Article :
Anti-tumor necrosis factor-alpha (TNF-alpha) therapies are not only beneficial for reducing symptoms in rheumatoid arthritis (RA) but also for structural damage visible on plain radiographs and serological biomarkers of articular cartilage damage. It is not known if these therapies also prevent stru...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/16206346

データ提供：米国国立医学図書館（NLM）

Etanercept's Positive Impact on Articular Cartilage in Ankylosing Spondylitis

Ankylosing spondylitis (AS), a chronic inflammatory condition primarily affecting the spine, presents a significant challenge for patients and healthcare providers alike. This study explores the potential benefits of etanercept, a TNF-alpha inhibitor, in mitigating the structural damage associated with AS. The authors investigate the effects of etanercept on articular cartilage biomarkers, aiming to understand its potential for protecting cartilage and slowing disease progression. This research delves into the complex interplay of inflammation and cartilage degradation in AS, seeking to identify potential therapeutic strategies for managing this challenging condition.

A Glimpse into the Potential for Cartilage Protection

The study found that etanercept had a positive impact on articular cartilage biomarkers, suggesting that it may help to protect and preserve cartilage in patients with AS. This research suggests that etanercept, like a refreshing oasis in the arid landscape of AS, may offer a potential solution for slowing disease progression and mitigating structural damage. The study's findings provide a promising avenue for future research, exploring the long-term effects of etanercept on cartilage health and disease progression in AS.

Navigating the Challenges of Ankylosing Spondylitis

Ankylosing spondylitis, like a stubborn desert sandstorm, can significantly impact quality of life. This research offers a glimmer of hope, suggesting that etanercept may be a valuable tool in the fight against this challenging condition. The study's findings provide valuable insights into the potential of TNF-alpha inhibitors to protect cartilage and slow disease progression, highlighting the importance of early diagnosis and intervention in AS. By understanding the complex interplay of inflammation and cartilage degradation, we can continue to develop effective strategies for managing this challenging disease and improving the lives of those affected.

Dr. Camel's Conclusion

As a researcher who has delved into the depths of inflammatory conditions, I find this study particularly encouraging. Etanercept, like a resilient camel navigating a harsh desert landscape, has shown promise in protecting articular cartilage in patients with AS. This research underscores the importance of continued research and innovation in developing effective therapies for inflammatory conditions. Remember, even in the most challenging deserts, there is always the potential for hope and healing.

Date :
  1. Date Completed 2005-12-13
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

16206346

DOI: Digital Object Identifier

0315162X-32-1911

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.